Life Sciences Infrastructure
A technology-first approach to drug development infrastructure. Our TEAMS framework delivers treatments 20% faster and 20% cheaper — ending the era of $2B, 12-year development cycles.
How We Got Here
Monument Square Group's focus has always been to find overlooked opportunities. We deployed the same lens when we were approached by life science experts to reimagine how life sciences is done. But what we discovered went far beyond physical infrastructure — it demanded a complete overhaul of people's perceptions and decades-old operations and processes. What we discovered changes everything.
Our roots
Our Strength: Pattern recognition.
Great things happen when we synthesize insights from disparate domains like change management, financial analysis, commercial real estate strategy, and operational systems and connect those perspectives with People, Ideas, and Capital.
The discovery
A culture of continuous learning, curiosity, and a willingness to take on hard projects opened the door to looking inside life sciences.
What we found wasn't just a story about equipment and physical infrastructure. The real story was the systemic problems hindering an essential industry. We studied the reasons for these massive inefficiencies and their impacts on people, processes, and the final product.
Now
Reimagining how life science is done
Our research showed that fundamental changes were needed — not in the science, but in the infrastructure around it. Rebuilding the infrastructure around technology instead of equipment means we can get treatments to patients everywhere faster and for less money. This is our mission and what we work on everyday.
The conviction
The major bottleneck in life sciences isn't the science. It's the infrastructure built to support it. No one has reimagined that infrastructure like we have.
Doing what others won't or can't do is what MSG has done from the beginning. Now we're applying our approach to the largest inefficiency affecting lives everywhere.
The Problem
Traditional drug development is locked in an equipment-centric model built decades ago. The infrastructure hasn't evolved. The only thing that has changed is the cost to bring treatments to patients has increased over the past 20 years.
The Traditional Model
Equipment-centric: Static, immobile equipment that is walled off from scientists
Siloed expertise: Researchers isolated across separate facilities
Linear processes: Sequential steps where each waits on the last
Capital inefficiency: Overhead and administrative costs consume disproportionate amounts of funding meant for research
The TEAMS Approach
Technology: Software-defined capabilities remove siloed data that hinders knowledge transfer and discourages collaboration
Efficiency: Scientists spend more time on the science and the mission
Automation: Amplifies scientists' impact at a time when they're being asked to do more with less
Modularity: Spaces that change with scientists' needs and reconfigure seamlessly
Scalability: The technology infrastructure scales as scientists' needs scale removing barriers to growth
20%
Faster development
timelines
20%
Lower capital
requirements
$2.3T
Global pharma market
addressable
The Opportunity
We sit at the intersection of market forces that have never aligned before — and the window to define this category is open now.
The life sciences industry has never seen a period like what we're in now - funding challenges, increased competition, uncertain regulation, technological upheaval, and the demand to produce treatments faster than ever.
A fresh, different approach is needed. This is where we excel. We analyze, synthesize, and execute our technology, infrastructure, capital, and life sciences expertise in a way no one else does.
We're not betting on a single new treatment. We're building the infrastructure layer — a whole new platform — that makes every drug development faster and cheaper.
Pharmaceutical companies currently spend $2B per approved drug on average. Even modest penetration of that inefficiency represents a generational opportunity.
Our Foundation
Nine principles, three dimensions. P3 cubed is how we evaluate our approach — and how life sciences innovation, infrastructure, and patient outcomes stay aligned.
Triple Bottom Line
We measure success by how quickly treatments reach patients. Every decision traces back to reducing the time critically ill patients wait.
20% cost reductions create superior returns for investors and lower treatment costs for patients simultaneously. Purpose and profit reinforce each other.
Modular infrastructure reduces waste, energy consumption, and the obsolescence inherent in traditional equipment-heavy development.
Strategic Relationships
We collaborate with universities and research hospitals to pilot next-generation lab environments that democratize access to cutting-edge capabilities.
From early-stage startups to pharma giants, we provide flexible infrastructure that scales with discovery — not against it.
We create environments where innovators, developers, and capital providers operate as one aligned system — not separate parties passing work down a chain.
Operational Excellence
20% faster timelines. 20% lower costs. 100% commitment to patient outcomes. We focus on what matters - improving people's lives.
Ending the era where $2B and 12 years stands between a scientific discovery and the patients who need it.
Building the infrastructure backbone for the next generation of life sciences — a commitment that compounds over decades.
Partner With Us
We're passionate about our mission and we like to talk with other passionate people. Reach out to us if you're an investor, a biotech innovator, or a development partner who shares our passion.
Or reach us directly at info@monumentsquaregroup.com